嘉必优: 嘉必优生物技术（武汉）股份有限公司关于发行股份及支付现金购买资产并募集配套资金暨关联交易报告书（草案）修订说明的公告

Core Viewpoint - The company plans to acquire 63.2134% equity of Shanghai Ouyi Biomedical Technology Co., Ltd. through a combination of issuing shares and cash payment, while also raising supporting funds [1] Group 1: Transaction Overview - The company intends to purchase assets and raise supporting funds, which involves a significant equity acquisition [1] - The transaction is subject to regulatory scrutiny, as indicated by the inquiry letter received from the Shanghai Stock Exchange [2] Group 2: Amendments and Updates - The company has revised its transaction report to address the requirements outlined in the inquiry letter and updated legal regulations [3] - Key updates include adjustments to the transaction plan, analysis of the impact on the company's equity structure and earnings per share, and additional agreements related to the transaction [3][4] Group 3: Risk Factors - The report highlights risks associated with the concentration of suppliers for production equipment and potential limitations in the procurement of related equipment and reagents [5]